ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection
ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection
复制标题
DOI：
10.1038/s41590-020-0773-7
复制
发表时间：
2020-08-17
影响因子：
30.5
通讯作者：
Valkenburg, Sophie A.
中科院分区：
文献类型：
--
作者：
Hachim, Asmaa;Kavian, Niloufar;Valkenburg, Sophie A.
准确的血清学检测是迫切需要的，以帮助诊断SARS-CoV-2感染。在这里，Valkenburg和同事们使用荧光素酶免疫沉淀系统来评估COVID-19患者对15种不同SARS-CoV-2抗原的抗体反应，并发现ORF 8和ORF 3b抗体，这些抗体一起作为一组点，在疾病的早期和晚期时间点识别了96.5%的COVID-19样本，特异性为99.5%。2型病毒于二零一九年十二月出现，并由于缺乏任何预先存在的免疫力而导致全球大流行。迫切需要准确的血清学检测来帮助诊断感染，确定过去的人群暴露情况，并评估对未来疫苗的反应。对SARS-CoV-2的抗体反应的情况尚不清楚。在这项研究中，我们利用荧光素酶免疫沉淀系统来评估COVID-19患者对15种不同SARS-CoV-2抗原的抗体应答。我们确定了SARS-CoV-2免疫应答的新靶点，并表明核衣壳、开放阅读框（ORF）8和ORF 3b引起最强的特异性抗体应答。ORF 8和ORF 3b抗体作为一组点，在疾病的早期和晚期时间点识别了96.5%的COVID-19样本，特异性为99.5%。我们的发现可用于开发第二代诊断测试，以改善COVID-19的血清学检测，并对了解致病性非常重要。
Accurate serology testing is urgently needed to help diagnose SARS-CoV-2 infection. Here Valkenburg and colleagues use a luciferase immunoprecipitation system to assess the antibody responses to 15 different SARS-CoV-2 antigens in patients with COVID-19 and find ORF8 and ORF3b antibodies, taken together as a cluster of points, identified 96.5% of COVID-19 samples at early and late time points of disease with 99.5% specificityThe SARS-CoV-2 virus emerged in December 2019 and has caused a worldwide pandemic due to the lack of any pre-existing immunity. Accurate serology testing is urgently needed to help diagnose infection, determine past exposure of populations and assess the response to a future vaccine. The landscape of antibody responses to SARS-CoV-2 is unknown. In this study, we utilized the luciferase immunoprecipitation system to assess the antibody responses to 15 different SARS-CoV-2 antigens in patients with COVID-19. We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses. ORF8 and ORF3b antibodies, taken together as a cluster of points, identified 96.5% of COVID-19 samples at early and late time points of disease with 99.5% specificity. Our findings could be used to develop second-generation diagnostic tests to improve serological assays for COVID-19 and are important in understanding pathogenicity.